Tickers

1. Composite Trajectory Verdict

All three statements carry roughly equal weight because BRKR is a capital-intensive scientific instrument manufacturer with significant acquisition activity, requiring assessment of profitability, cash generation, and leverage.

Composite Trajectory: Deteriorating

The composite trajectory is driven by a sharp deterioration in earnings and cash generation, partially offset by a mixed balance sheet picture. GAAP operating income fell 73% year-over-year to $68.2 million (2.0% margin) from $253.1 million (7.5% margin), and the company swung to a net loss of $8.3 million from net income of $113.8 million (10-K FY2025, Consolidated Statements of Operations). Operating cash flow declined 47% to $134.1 million from $251.3 million, and non-GAAP free cash flow fell 68% to $43.3 million from $136.0 million (10-K FY2025, Consolidated Statements of Cash Flows; MD&A Non-GAAP Measures). The balance sheet shows reduced long-term debt ($1,852.5 million vs $2,061.8 million) and higher equity ($2,473.5 million vs $1,797.1 million) following a $690 million preferred stock issuance, but a $96.5 million goodwill impairment signals asset quality concerns (10-K FY2025, Consolidated Balance Sheets; Note 6 Goodwill and Intangible Assets).

2. Red Flags

• GAAP operating income declined 73% YoY to $68.2 million (2.0% margin) from $253.1 million (7.5% margin) (10-K FY2025, Consolidated Statements of Operations).
• Net loss of $8.3 million in FY2025 versus net income of $113.8 million in FY2024 (10-K FY2025, Consolidated Statements of Operations).
• Gross margin compressed 310 basis points to 45.9% from 49.0% (10-K FY2025, Consolidated Statements of Operations).
• Operating cash flow fell 47% YoY to $134.1 million from $251.3 million (10-K FY2025, Consolidated Statements of Cash Flows).
• Non-GAAP free cash flow dropped 68% to $43.3 million from $136.0 million (10-K FY2025, MD&A Non-GAAP Measures).
• Goodwill impairment of $96.5 million recorded in Q3 2025 related to Bruker Spatial Biology and Automation reporting units (10-K FY2025, Note 6 Goodwill and Intangible Assets).
• Restructuring costs surged to $77.4 million (non-GAAP adjustment) from $24.7 million in FY2024 (10-K FY2025, MD&A Non-GAAP Measures).
• Effective tax rate spiked to 133.2% in FY2025 from 44.2% in FY2024 due to jurisdictional mix and impairment impacts (10-K FY2025, MD&A Income Tax Provision).
• Tariff increases adversely impacted cost of goods sold and gross margins in FY2025 (10-K FY2025, MD&A Global Tariffs).
• Non-GAAP operating margin declined 280 basis points to 12.6% from 15.4% (10-K FY2025, MD&A Non-GAAP Measures).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Revenue grew only 2.1% to $3,436.5 million from $3,366.4 million, but cost of revenue rose 8.3%, driving gross profit down 4.4% to $1,577.7 million and gross margin down 310 bps to 45.9% (10-K FY2025, Consolidated Statements of Operations). Operating expenses increased 8.1% to $1,509.5 million, including a $96.5 million goodwill impairment charge and $77.4 million in restructuring costs (non-GAAP adjustment) (10-K FY2025, Consolidated Statements of Operations; MD&A Non-GAAP Measures). Operating income collapsed 73% to $68.2 million (2.0% margin) from $253.1 million (7.5% margin). Net income turned negative at -$8.3 million versus $113.8 million in FY2024, and basic EPS fell to -$0.15 from $0.76 (10-K FY2025, Consolidated Statements of Operations). Segment operating income declined across all four segments, with BSI NANO swinging to a -$71.8 million loss from $2.3 million profit (10-K FY2025, MD&A Operating Income).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash provided by operating activities fell 47% to $134.1 million from $251.3 million, driven by lower net income adjusted for non-cash items ($278.9 million vs $329.5 million) and a larger negative change in operating assets and liabilities (-$144.8 million vs -$78.2 million) (10-K FY2025, Consolidated Statements of Cash Flows). Capital expenditures decreased to $90.8 million from $115.3 million, but non-GAAP free cash flow still declined 68% to $43.3 million from $136.0 million (10-K FY2025, Consolidated Statements of Cash Flows; MD&A Non-GAAP Measures). Cash paid for taxes jumped to $222.5 million from $153.9 million, and cash paid for interest rose to $71.0 million from $54.6 million (10-K FY2025, Consolidated Statements of Cash Flows). Investing cash outflows slowed dramatically (-$196.5 million vs -$1,757.3 million) due to fewer acquisitions, while financing activities provided $135.1 million net, primarily from the $669.7 million preferred stock issuance offset by $466.5 million in debt repayments (10-K FY2025, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew to $6,241.4 million from $5,806.7 million, while total liabilities decreased to $3,731.1 million from $3,991.5 million (10-K FY2025, Consolidated Balance Sheets). Long-term debt was reduced to $1,852.5 million from $2,061.8 million following repayments funded by the Series A Mandatory Convertible Preferred Stock issuance ($690 million liquidation preference) (10-K FY2025, Consolidated Balance Sheets; MD&A Issuance of Series A Mandatory Convertible Preferred Stock). Shareholders' equity attributable to Bruker Corporation increased to $2,456.5 million from $1,781.2 million, reflecting the preferred stock issuance and accumulated other comprehensive income improvement (10-K FY2025, Consolidated Balance Sheets). However, goodwill remains high at $1,547.7 million (up from $1,507.3 million) with a $96.5 million impairment charge in FY2025, and inventories rose to $1,094.6 million from $1,067.8 million while accounts receivable fell slightly to $544.9 million from $565.5 million (10-K FY2025, Consolidated Balance Sheets; Note 6 Goodwill and Intangible Assets). The revolving credit facility has $899.3 million available of $900.0 million capacity (10-K FY2025, MD&A Debt and Credit Facilities).

6. Data Gaps

• Quarterly revenue, operating income, and cash flow trends for Q1–Q4 2025 and Q1–Q2 2026 (10-Q filings truncated in provided documents).
• Segment-level cash flow statements for any period.
• Detailed debt maturity schedule beyond the fact that the 2019 term loan and 2024 revolving credit agreement were repaid.
• Organic revenue growth rate for FY2025 on a GAAP basis (filing only provides non-GAAP organic revenue growth of -3.7%).
• Breakdown of restructuring costs by segment and type for FY2025 beyond the aggregate non-GAAP adjustment.
• Quantitative impact of tariffs on cost of goods sold and margins in FY2025 (only qualitative disclosure provided).
• Pro forma financials for 2025 acquisitions (Recipe, AST, etc.) to assess full-year contribution.